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Abstract 
 
Background: There are concerns over the quality of generics medicines in Pakistan. This is due to 
perceived noncompliance with Good Manufacturing Practice (GMP), whereby the quality of the raw 
materials is not being assessed. If not addressed, this will impact on the potential for generics 
exports from Pakistan, as well as on patient care. Consequently, there is a need to assess the 
current assessment and regulatory situation in Pakistan and to recommend a way forward that 
ensures the future quality of products. 
Objective: Assess the quality of the raw materials that are either imported to, or manufactured in 
Pakistan, that are then used to produce a leading analgesic (ibuprofen). As part of the assessment, 
the presence and levels of impurities will be determined. Subsequently, the findings will be used to 
recommend potential regulatory changes to improve patient care.  
Methods: Assess the quality of 27 sourced raw materials and the reference product using a variety 
of quality assessment methodologies, including assay tests and Infrared spectroscopy and UV-
spectrophotometry, and comparing these to values documented in the Certificate of Analysis (CoA), 
and HPLC chromatography.  
Results and discussion: All but one sample passed the spectroscopy identification tests. However, 
81.5% of samples failed to comply with pharmacopeia assay limits. There were also concerns with 
the use of HPLC methods to assess the quality of raw materials , and over the fact that assay values 
obtained were not the same as those listed in the CoA. In addition, where manufacturers had 
concerns over the amount of ibuprofen in the raw material, rather than rejecting the product, they 
typically used higher quantities to make up any shortfall. This demonstrates that there is an urgent 
need to improve the registration process for generic products  in Pakistan. This will include 
implementing Common Technical Documents (CTDs) based on international standards. In this way, 
we will see generics being produced that result in improved patient care and that have potential for 
export from Pakistan.      
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Introduction 
 
The pharmaceutical market in Pakistan was worth approximately 2.3 billion USD in 2014 [1]. At present, 
Pakistan can produce a variety of medicines and meets approximately 90% of the demand for domestic 
finished products. However, Pakistan currently only produces  a limited amount of Active Pharmaceutical 
Ingredients (APIs) needed for medicines consumed in Pakistan [2], with more than 90% of raw materials / 
APIs coming from China and India. 
 
There are concerns over the quality of medicines manufactured in Pakistan due to perceived 
noncompliance with Good Manufacturing Practice (GMP) requirements outlined by pharmaceutical 
manufacturers [3]. These include checks on the quality of APIs being used to produce oral tablets [3]. 
GMP requirements are included in the Drug (Licensing, Registering and Advertising) Rules (Schedule-B 
II), which were enacted in Pakistan in 1976 [4]. However, since then, GMP and other registration 
requirements have not been updated [5]. This means that there have been no updates or revisions 
following the creation of international standards or WHO guidelines [6].  With over 1200 registered 
medicines and over 80,000 registered drug products in Pakistan [5], coupled to physician concerns over 
the safety and efficacy of lower cost generics, the country sees high levels of prescribing of originator 
products [5,7,8]. This is a public health concern as self-pay for medicines in Pakistan is widespread [9] 
and therefor there are implications for affordability and subsequent adherence rates, especially for 
treatment of chronic diseases affecting the lower paid [10-12]. Patient care is not compromised with 
generic medicines that meet agreed quality standards, including bioequivalence levels, across a wide 
range of disease areas [13-19]. Concerns over generic immunosuppressants are also reducing [20].  
 
There is inconsistency between the information to be included in application dossiers required for 
authorizing a medicine in Pakistan by the Drugs (Licensing, Registering and Advertising) Rules, 1976, 
and those stated in the DRAP (Drug Regulatory Authority of Pakistan) Act, 2012 [21]. In this Act, 
Schedule-I states that the pharmaceutical dossier should include a set of the following documents for 
submission that give all information on the technical aspects of a product¶s manufacture.  
 
a. Master formula;  
b. All ingredients both active pharmaceutical ingredients and inactive excipients added with their 
safety profile data;  
c. Complete manufacturing procedure of the drug, biological or medical device;  
d. Quality control steps and procedures at each level of raw material selection, in-process testing, 
finished drug testing, and stability testing;  
e. Clinical trial data and published reports about the safety and efficacy of the drug;  
f. Complete details of manufacturing plant and equipment, quality control laboratories and 
equipment;  
g. Ware-houses capacities and facilities; details of human resources available and the latest cGMP 
report shall also be part of this document set;  
h. Any other information required by the Registration Board for establishing the safety, efficacy, 
bioavailability, bioequivalence, or bio-similarity of the drug. 
 
Section 7 (c) (ix) of the DRAP Act, also emphasizes the systematic implementation of the ICH 
(International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use),  
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WHO and FDA guidelines [3, 6,22]. All these guidelines suggest that application for the registration of 
medicines in a country should follow an internationally harmonized format known as the CTD (Common 
Technical Document). The CTD consists of five modules [23]:  
x Module 1 Region-specific Administrative information  
x Module 2 Quality overall summary (Overview and summary of modules 3 to 5) 
x Module 3 Chemistry manufacturing and Controls (Quality) 
x Module 4 Non-clinical / Preclinical (Safety) 
x Module 5 Clinical (Efficacy)  
 
However, despite many developing countries implementing such standards, they are not implemented in 
Pakistan, demonstrating the continued weaknesses this registration process [5]. 
 
The quality of medicines in Pakistan is of major concern. DRAP is currently unable to effectively check the 
quality of all APIs and finished products through the available surveillance testing laboratories that are 
under governmental control. These materials are typically only tested to be quantified, and not for the 
identification of impurities, nor do they undergo any other pharmacopeia tests. In addition, most of the 
laboratories involved in conducting these tests appear to contain out-dated instruments and materials, 
and there are concerns over levels of staff training and availability, as only a limited number of staff have 
been hired in recent years. This is despite such regulations being part of current laws [24].  
 
The medicine registration process in any country is key to the availability of adequate medicines that 
meet agreed quality targets. Concerns over the quality of generics produced in Pakistan is currently 
resulting in low exports [25] and impacting on patient care, especially for patients with chronic diseases. 
 
There are also concerns that the basic and semi-basic industry involved in the manufacture of raw 
materials in Pakistan has not flourished due to unfavorable policies towards the protection or security of 
businesses. This is reflected by the fact that only 33 manufacturing units are currently involved in basic or 
semi-basic manufacturing of pharmaceuticals in Pakistan [26]. This compares with approximately 600 
active licensed manufacturers of finished products in Pakistan [27]. In addition, among these 33, only 7 
manufacturing units currently appear active further demonstrating problems with current policies [26].  
 
Objectives 
 
Considering these concerns, the objective of this study was to assess the quality of APIs in Pakistan and 
to use this as a starting point for suggesting improvements in the registration process for oral generic 
tablets. We chose ibuprofen for our study in view of the extent to which it is prescribed in Pakistan, which 
is 12% by value of the analgesic market. The analgesic market currently has a growth of 20% per annum 
[28].  In addition, APIs are produced both locally and are imported. For ibuprofen, there are specific 
concerns relating to potential impurities in the light of pharmacopoeia specifications. The findings will 
subsequently serve as a guide to suggest improvements for the pharmaceutical drug registration process 
in Pakistan, to ensure good quality, safe, effective and affordable medicines are produced that will help 
improve patient care in Pakistan, and potentially boost exports.    
 
Methodology 
 
Collection of Ibuprofen API samples 
27 samples of ibuprofen APIs used by manufacturers in Pakistan were obtained, together with their 
Certificate of Analysis (CoA). The CoAs contained details regarding the results of tests and their values 
and limits (including assay values) of relevant batches, as well as information about the manufacturer. 
The US Pharmacopeia (USP) reference standard ibuprofen was obtained from Abbott Laboratories, 
Pakistan (originator manufacturer of ibuprofen). Coding was undertaken on all collected samples, with all 
samples stored in closed containers. Desiccators were used to avoid moisture absorption.  
 
Quality assessment: 
The quality assessment of the ibuprofen samples was performed using the following methods:  
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1. Identification test 
All samples were identified using the following two methods: 
x FTIR (Fourier Transform Infrared) Spectroscopy. In this method, dry samples were used and placed 
in the instrument after cleaning with methanol. The HazMat ID (Smiths Detection, USA) instrument 
was used for this purpose. The results from the HazMet (FTIR Analyzer) were interpreted from 
percentage resemblance, rather than being represented as concordant or not concordant with the 
reference spectrum. 
x UV-Spectrophotometry. The UV identification WHVWIRULEXSURIHQLVWKHUDWLRRIWKHDEVRUEDQFH¶VDW
264nm and 273nm, reported again as percentage difference to the USP reference standard, and 
not as a pass/fail  
 
For all API samples and the USP Reference Standard (Abbott Laboratories, Pakistan), the solutions were 
prepared in 0.1 N Sodium Hydroxide with a concentration of 0.025 g per 100 ml, equivalent to 250 µg per 
ml of ibuprofen. Respective absorptivities at 264 nm and 273 nm on the anhydrous basis were noted.  
 
For the UV-Spectrophotometer limits, the absorptivities were calculated on an anhydrous basis, and 
should not differ by more than 3.0% at 264 nm and 273 nm, as per USP limits.  
 
The testing of ibuprofen against USP specifications was undertaken in one of the country's highest 
standard laboratories, declared as the "Appellate Laboratory" of the country. The utilization of a USP 
approved laboratory to undertake the testing has significance in terms of the reliability of the results, 
negating the need to test the samples in other USP international laboratories in either Brazil, China or 
India.
  
2. Assay Test 
USP specifications mention the following limits for assay testing, ³,EXSURIHQ $FWLYH 3KDUPDFHXWLFDO
Ingredient) contains not less than 97.0 percent and not more than 103.0 percent of C13H18O2, calculated 
RQ WKH DQK\GURXV EDVLV´ >9]. The USP only documents one related / impurity substance, this is in 
contrary to the BP specifications where 18 substances are mentioned. However, the identification and 
characterization of related / impurity substances is out of the scope of this paper. 
 
The Assay Test procedure 
Mobile phase: 
Chloroacetic acid (4.0 g) was dissolved in water (400 ml) and then adjusted to a pH of 3.0 with 
ammonium hydroxide. Acetonitrile (600 ml) was added, then filtered, and degased. Amendment or 
modifications were done as per the requirements of System Suitability. 
 
Preparation of Standard Solution: 
A solution with concentration of about 12 mg per ml was prepared by dissolving USP Ibuprofen RS 
(accurately weighed) in Internal Standard Solution.  
 
Assay preparation 
1200 mg of ibuprofen, accurately weighed, was transferred to a 100-ml volumetric flask, diluted with 
Internal Standard Solution to volume, and mixed. Table 1 contains details of the chromatographic 
conditions. 
 
The L1 column packing used was Octadecysilane C18 as C18 is generally more retentive than C8,  
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Table 1 - Chromatographic conditions / system requirements  
 
Instrument Ultra fast HPLC SIL-30AC 
Analytical Column Column with L1 packing and dimensions of 4.6 mm × 25 cm  
Mobile Phase Chloroacetic acid (4.0 g) dissolved in water (400 ml) and 
adjusted to a pH of 3.0 with ammonium hydroxide. 
Acetonitrile (600 ml) was added, filtered, and degased. 
Flow rate 2.0 ml per minute 
Injection volume 5 µl 
Detector UV at 254 nm  
 
Test for system suitability 
The peak response was recorded after repeated injections of 5 to 6 consecutive standard solutions before 
injecting the sample solutions. This was repeated after completion of work, to observe the consistency of 
performance of the system. 
 
Acceptability criteria 
The qualification criteria for the system suitability test was that there should be less than 2% Relative 
Standard Deviation (RSD) for 5 replicate injections of the standard solution, with not more than 2.5 tailing 
factors for the individual peaks. 
 
Procedure 
Equal volumes (approximately 5 µL) of the Standard preparation and the Assay preparation were 
separately injected into the chromatograph. Chromatograms were recorded and the response for the 
major peaks were measured.  
 
The quantity of ibuprofen in mg was calculated using the formula: 100 C (RU / RS) where: 
x C is the concentration, in mg per ml, of USP Ibuprofen RS in the Standard preparation; and  
x RU is the peak response ratios obtained from the Assay preparation; and  
x RS is the peak response ratios obtained from the Standard preparation. 
 
Results:  
 
1. Identification test: 
 
Through FTIR (Fourier Transform Infrared Spectroscopy)  
 
Table 2 documents the percentage resemblance of the FTIR spectra of the 27 samples, to the USP 
standard spectrum. It also shows the percentage difference between the 27 samples and the USP 
standard spectrum, for the 264 nm and 273 nm peaks, recorded via UV-Spectrophotometry. 
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Table 2 ± Results of FTIR spectrometry, and UV-Spectrophotometry at 264 nm and 273 nm
 
S. 
No. 
Sample 
Name 
Percentage 
resemblance 
through FTIR 
Absorption 
at 264 nm 
Percentage 
difference 
(%) 
Absorption 
at 273 nm 
Percentage 
difference 
(%) 
1.  USP 
Standard 
100 0.450 - 0.350 - 
2.  IBU-1 99.8 0.450 0 0.354 0.4 
3.  IBU-2 99.7 0.446 0.88 0.349 0.1 
4.  IBU-3 98.8 0.465 1.5 0.365 1.5 
5.  IBU-4 99.3 0.477 2.7 0.379 2.9 
6.  IBU-5 99.4 0.433 1.7 0.342 0.8 
7.  IBU-6 99.6 0.459 0.9 0.352 0.2 
8.  IBU-7 99.2 0.436 1.4 0.337 1.3 
9.  IBU-8 99.7 0.450 0 0.351 0.1 
10.  IBU-9 99.6 0.445 0.5 0.352 0.2 
11.  IBU-10 99.3 0.460 1.0 0.357 0.7 
12.  IBU-11 99.6 0.449 1.0 0.354 0.4 
13.  IBU-12 98.6 0.448 0.2 0.348 0.2 
14.  IBU-13 96.9 0.425 2.5 0.329 2.1  
15.  IBU-14 87.0 0.409 4.0 0.319 3.1 
16.  IBU-15 98.5 0.439 1.1 0.344 0.6 
17.  IBU-16 97.2 0.430 2.0 0.335 1.5 
18.  IBU-17 98.9 0.448 0.2 0.339 1.1 
19.  IBU-18 99.0 0.435 2.0 0.335 1.5 
20.  IBU-19 98.1 0.484 3.4 0.363 1.3 
21.  IBU-20 97.7 0.441 0.9 0.343 0.7 
22.  IBU-21 97.9 0.429 2.1 0.338 1.2 
23.  IBU-22 96.8 0.433 1.7 0.337 1.3 
24.  IBU-23 95.0 0.428 2.2 0.335 1.5 
25.  IBU-24 92.5 0.450 0 0.350 0 
26.  IBU-25 96.2 0.461 1.1 0.365 1.5 
27.  IBU-26 93.2 0.434 1.6 0.334 1.6 
28.  IBU-27 94.0 0.417 3.3 0.323 2.7 
 
 
For measurements taken on the same day, precision ranged from 0.23% to 0.62%, and accuracy ranged 
from 99.6% to 100.3%. For measurements taken on different days, precision ranged from 0.24% to 
0.52%.
 
2. Assay values: 
 
Table 3 documents the assay values of the 27 samples and the ibuprofen USP reference standard. 
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Table 3 ± Ibuprofen assay values. 
 
S. 
No. 
Sample Name Percentage 
assay 
quantity 
Assay 
value 
claimed in 
the COA 
Difference in assay value 
obtained 
experimentallycompared 
to that claimed in COA 
(%) 
1.  USP Standard 100 - - 
2.  IBU-1 92.51 100.4 7.89 
3.  IBU-2 96.87 99.81 2.94 
4.  IBU-3 97.84 99.00 1.16 
5.  IBU-4 96.69 99.50 2.81 
6.  IBU-5 97.08 99.75 2.67 
7.  IBU-6 97.40 99.80 2.4 
8.  IBU-7 96.15 99.50 3.35 
9.  IBU-8 96.39 99.90 3.51 
10.  IBU-9 96.53 99.80 3.27 
11.  IBU-10 95.51 99.50 3.99 
12.  IBU-11 94.70 99.30 4.6 
13.  IBU-12 96.72 99.40 2.68 
14.  IBU-13 92.69 99.87 7.18 
15.  IBU-14 99.15 99.80 0.65 
16.  IBU-15 95.50 99.50 4 
17.  IBU-16 97.85 99.10 1.25 
18.  IBU-17 94.48 99.10 4.62 
19.  IBU-18 94.90 99.60 4.7 
20.  IBU-19 96.33 99.20 2.87 
21.  IBU-20 94.80 99.80 5 
22.  IBU-21 94.39 99.84 5.45 
23.  IBU-22 96.31 99.10 2.79 
24.  IBU-23 94.85 99.50 4.65 
25.  IBU-24 96.19 99.87 3.68 
26.  IBU-25 95.70 99.00 3.3 
27.  IBU-26 96.53 99.51 2.98 
28.  IBU-27 95.60 99.87 4.27 
 
Discussion 
 
The results reveal both positive and concerning aspects surrounding the APIs currently used in the 
production of generic ibuprofen tablets in Pakistan. 
 
All samples, except sample IBU-14, passed the Identification test through FTIR and UV methods as per 
the requirements of USP specifications (Table 2). Using the analytical methodology or 
assessmentsuggests that 96 % API samples passed the test and can be approved and marketed as 
ibuprofen. 
 
However, 22 out of 27 (81.5%) of the ibuprofen samples failed to comply with the USP assay limits, i.e. 
97 % to 103 %. Interestingly, sample IBU-14 passed this test with highest percentage of assay value, i.e. 
99.15% (Table 3). IBU-14 also showed minimal difference in assay value to the values mentioned in the 
product CoA (Table 3).
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Secondly, one extra peak was noticed in the chromatograms of six (18.5 %) of the samples, i.e. IBU-3, 
IBU-4, IBU-5, IBU-10, IBU-19 and IBU-25, at approximately the same time, i.e. between 3.1 to 3.3 
minutes.  
 
Thirdly, the comparison of assay values obtained using our methodology, versus those claimed by the 
manufacturer in their CoA (Table 3), shows that none of the samples complied with the assay values 
claimed in their CoAs. Instead, three (11%) of the samples showed more than a 5 % difference in assay 
value. In the majority of cases, the manufacturers of the finished products did not perform any testing on 
the API supplied. Instead, they typically rely on the CoA. This should be of concern to both regulators and 
manufacturers. Regulators in terms of the implementation of cGMP while manufacturers should ethically 
and legally be responsible to follow cGMP for their finished products. In cases where product 
manufacturers perform tests on the APIs, when assay values of API are found to be lower than the 
prescribed limits, instead of rejecting the raw material or API, they typically use higher quantities in the 
production of ibuprofen tablets based on their own calculations, which raises concerns over the quality of 
products (S. Hussein Personal Communication).  
 
Our findings show a general failure of the current system of drug regulation in Pakistan that surrounds the 
quality of APIs used for drug production. This is in line with previous publications [5]. This will negatively 
impact on the quality of finished generic products for use in patients and will potentially compromise 
patient care. The results also show that quality assessment of multiple source medicines should not rely 
on Assay testing alone. Other pharmacopeia tests are also important, especially in cases where the 
optical activity and the presence of genotoxic, and other impurities, have a critical impact or role regarding 
the efficacy, safety and quality of medicines. Here, the failing sample of ibuprofen (IBU-14) passed the 
assay test with the highest value, while the sample failed the identification test. This invites scientific 
discussion regarding the value of current assay testing for generics in Pakistan  (Table 2). The results 
suggest that IBU-14 was not a pure API of ibuprofen. Instead, it may contain related substances or 
impurities which have a very close structural resemblance to the API of ibuprofen and the HPLC method 
used could not identify these or discriminate them from the actual API of the drug [30]. This is why the 
USP  does not mention the use of the HPLC method for the Identification Testing of Ibuprofen API. 
Consequently, the USP compendium of methods for the identification of Ibuprofen API, i.e. the FTIR and 
UV-Spectrophotometer methods, should be used in the future to assess the content of APIs in Pakistan.  
 
The extra peak in the chromatograms, at 3.1 to 3.23 minutes, is also an important observation. When 
samples IBU-3, IBU-4, IBU-5, IBU-10, IBU-19 and IBU-25 (18.5 %) were investigated for their source of 
manufacturing, it was found these samples were procured from only  three sources. Two were in Pakistan 
(B and H) and one was in India (C). Further appraisal revealed that all APIs purchased from sources C 
and H showed this extra peak at the same time range. This illustrates the necessity to perform 
prequalification studies to evaluate the quality of the API from pharmaceutical manufacturers, before 
turning the raw materials into finished goods. However, only 2 out of 7 (approx. 29 %) API samples 
purchased from source B showed this extra peak. These results need to be further investigated for the 
characterization of this peak through evaluation of the route of synthesis or method of manufacturing of 
the API in order that potential corrective and preventive measures can be suggested for the future. It 
seems that this extra peak may be due to residual solvent or impurities remaining in the API. However, 
this needs further investigating before any definitive statements can be made. We are aware that both the 
BP and European Pharmacopoeia include a test for related substances for ibuprofen, with 18 potential 
impurities listed in the BP. However, as mentioned previously, the USP mentions only one specific 
impurity.  
 
Assessment of the Drug Registration Process and Requirements in Pakistan 
 
In view of the findings regarding the careful assessment of the current procedures concerning the 
registration of medicines in Pakistan, the technical requirements outlined in Box 1 are a potential way 
forward to improve the quality of medicines in Pakistan. 
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Box  1 ± Suggested technical requirements for registering medicines in Pakistan  
 
1. Pharmaceutical Development Studies for establishment of a master formulation (Q-8 - ICH). 
2. Stability studies (Q-1 - ICH). 
3. Validation studies (for manufacturing method and analytical procedures). 
4. Studies verifying suitability and establishment of specifications of packaging material / container 
closure system. 
5. Indigenous clinical trials for new and imported drugs and / or bioequivalence studies of already 
registered (generic) drugs. 
6. Approval of Clinical Prescribing Information (e.g., indications, dose etc.) like SmPC (Summary of 
Product Characteristics) and PIL (Patient Information Leaflet). 
7. Establishment of Finished Pharmaceutical Product Specifications through equipment qualification, 
method transfer, system suitability, and analytical method validation. 
8. Qualification of source of materials (Actives and Inactives etc.). 
9. Use of approved / authentic primary and secondary references in analytical techniques.  
10. Authorization / Approvals of the marketing literature (e.g., detailing material). 
11. Description of activities related to Adverse Drug monitoring / Pharmacovigilance 
 
Currently, medicines being registered in Pakistan are not being fully evaluated for their safety and quality 
especially in terms of their APIs [5]. Some of the suggested requirements (Box 1) are currently not a 
mandatory part of the registration of medicines in Pakistan, e.g. the bioequivalence of generic medicines 
and even submission of the SmPC and the PIL. Others, which are covered under the current rules and 
procedures, are also not currently being completely fulfilled, such as: performing stability studies and 
validation studies. Ethically and legally, applicants should be bound to these commitments and thus 
perform these studies before marketing the medicines. However, in reality very few companies are 
complying these commitments and performing such studies before marketing their medicines (S. Hussein 
personal communication). There was a recent incidence of fake medicines at the Punjab Institute of 
Cardiology which is thought to be a direct result of such deficiencies in the registration process and 
negligence with following cGMP [31, 32]. 
  
Despite these concerns, pharmaceutical manufacturers in Pakistan currently appear reluctant to perform 
additional tests or provide more comprehensive information about their medicines, during and after 
registration. This is thought to be due to the potential negative impact this could have on business (S. 
Hussein Personal Communication). In fact, the reverse may be true which would lead to improvement in 
the quality of generics for consumption in Pakistan, and a greater potential for export to other countries. 
 
Recommendations: 
 
Here we outline a number of recommendations that should be considered by the Pharmaceutical 
Evaluation and Registration (PE & R) Division within the Drug Regulatory of Pakistan (DRAP), in 
consultation with Pakistani Pharmaceutical companies, to improve the quality of generics produced by 
domestic manufacturers for use in Pakistan as well as for exportation. 
 
These include a step-wise plan for the implementation of CTDs and new requirements in line with ICH 
standards, over 1 to 3 years, e.g.: 
x Step 1: For new drugs, imported drugs and narcotic and Psychotropic Drugs (Two to six months) 
x Step 2: For Biological (other than imported) and Anticancer drugs. (Two to six months) 
x Step 3: For Anti-T.B, anti-HIVAIDs and Anti-malarial drugs (other than) and Anticancer drugs. (Two to 
six months) 
x Step 4: For all Antibiotics. (Two to six months) 
x Step 5: For all Essential Drugs (except OTC). (Two to six months) 
x Step 6: For Cardiovascular and Anti Diabetes Drug. (Two to six months) 
x Step 7: For all remaining drugs. (Two to six months) 
 
Alternatively: 
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x In the first-phase, requirements already set out by the current rules and regulations should be 
implemented. This requires no additional effort by the manufacturers to carry out stability studies of API 
and Drug master files (open part) of the APIs and submission of the established SmPC (Summary of 
Product Characteristics) and PIL (Product Information Leaflet) of the product. This phase may take 3 to 6 
months 
x In the second-phase, there should be implementation of pertinent technical requirements which 
are not currently covered under the existing rules and regulations, such as bioequivalence studies. This 
will require more time as changes or improvements must be made to the infrastructure of DRAP 
 
Recently, the efforts of DRAP, in collaboration with USP and the WHO, to develop the ³Road Map for 
Strengthening the Registration System of Pharmaceutical Products and Biologicals for Human / 
Veterinary Use in Pakistan´ demonstrates a noticeable step towards improving the quality of medicines in 
Pakistan. We will be monitoring its progress and making additional recommendations if necessary.  
 
Together with this, there is the ongoing process that seeks to convince pharmaceutical companies 
through discussions, seminars, and dialogue, of the need to adopt these new requirements for drug 
registration, to improve patient care and the potential for drug exports. The experiences of other countries 
that have started to accept such registration dossiers on CTD or e-CTD, should also be communicated 
within Pakistan  to enhance acceptance of updated requirements. These countries include: Australia, 
Canada, China, Croatia, Japan, Saudi- Arabia, Singapore, South Africa, Switzerland, US, and all EU 
Member States [33]. In addition, comparison with the pharmaceutical manufacturing industry in Jordan 
whose population is only 8 million compared with 201 million in Pakistan. Jordan currently has 16 
pharmaceutical units compared with over 600 units in Pakistan [26, 34]. However, their exports are high 
with over 80% of produced medicines currently being exported over 60 countries [34, 35]. This includes 
more than US$4.5 billion alone to Saudi Arabia alone [35]. In contrast, Pakistani manufacturers in 2013 
only exported US$1Billion due to concerns with poor quality [25, 36].  
 
The implementation of ICH Standards should also be applicable to already registered medicines. These 
improvements may be achieved in the same step-wise manner as described above at the time of their 
application for renewal of registration starting over the coming year. 
 
Other recommendations may include: 
x Improved tracking of agreed implementation issues, maintained through dialogue sessions with 
pertinent pharmaceutical companies under political & governmental control, with the help of external 
organisations such as the WHO. This should help speed up the adoption of new processes to 
improve the quality of generics in Pakistan 
x During the transition period and prior to mandatory implementation, voluntary compliance with agreed 
new data requirements is advocated. Collection of BE (bioequivalence) data, should also be 
encouraged. This could be achieved through faster approval times and other beneficial regulatory 
aspects. 
x Preparation of a minimum checklist, providing guidance to manufacturers on specific documentation 
requirements to reduce impurities and improve the quality of API raw materials. Internal staff within 
the regulatory agencies in Pakistan should familiarize themselves with, and gain an in depth 
knowledge of the revised/new requirements. This can be done through attending internal and external 
training programmes and sharing information amongst peers. 
x Providing manufacturers with additional motivation hasten or oblige the adoption of these new 
requirements. This could include shorter approval times for pending applications / post registration 
variations. 
 
Manufacturers and the DRAP may consider the following technical aspects whilst undergoing 
prequalification of API sources: 
x Assessment of API dossier  
x Inspection of manufacturing sites 
x Random sampling and testing 
x Details about handling of complaints and recalls 
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x Periodic or continuous checks to maintain the prequalification status  
x Requirements for assessment of quality from DMF (Drug Master File) or APIMF (Active 
Pharmaceutical Ingredient Master File), together with the open part and closed part details. 
 
If these measures are adopted, patients can expect good quality generics in the future. This is important 
given, the extent to which medicines in Pakistan are self-pay. Without such measures, patient care using 
generics and trust in the healthcare system will continue to be compromised, and there will be increased 
potential for adverse drug reactions [37]. Successful steps have already been taken to address concerns 
over counterfeit medicines in Pakistan, which need to continue [38]. The above considerations should be 
the next step to further improve the availability of safe, effective and affordable medicines in Pakistan. 
This is of great importance given the increasing prevalence of chronic illnesses and diseases in this 
country, where every third person over the age of 40 is vulnerable to a wide range of diseases [39], and 
70% of the population live on less than 2 USD per day [40]. 
 
Conclusion 
 
The results of this study document the concerns over the current regulations for assessment of the quality 
of drug raw materials (APIs) in Pakistan. These need to be urgently addressed to ensure good quality 
generics in Pakistan for patients, and to improve potential export opportunities.  The adoption of the WHO 
and ICH recommended CTD format and WHO prequalification guidelines, to improve the process of 
registration of medicines in Pakistan, should help improve the current system for registering medicines. 
Thus, this will enhance the availability of safe, effective and cost-effective generics for patients in 
Pakistan and other regions. This is starting to happen and will be monitored. 
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